Sign In
NewsRadar

Bionexis Pharmaceuticals

Bionexis specializes in the design and development of intelligent molecules for imaging and therapeutic applications. The technology is based on unique know-how on membrabe protein-lipid interactions, focused on pathological APOPTOSIS. Initial applications being developed are int he areas of oncology, inflammation and cardiovascular disease.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 

Phone:
Web:
Contact:
 
 
Paris Biotech
4 venue de l'observatoire
Paris 75006
France
+33 (0)1 5373 1551
http://www.bionexis.com
Brid T Rodgers
+33 (0)6 7017 3576

Company Facts
Founded:Feb 2000
Founders:Francoise Russo-Marie, Alain Samson
CEO:Brid T. Rodgers
CTO or technical lead:
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:Startup
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


24,583
Tech investments
From our Online Data Service
15,902
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 10€19.0MBusiness applications
Aug 10N/APayment software
Aug 10€1.4MInternet services
Aug 10€0.8MPayment software
Aug 10€3.7MArtificial Intelligence
Aug 10€73.0MBiopharmaceuticals
Aug 9€11.4MWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises 37.5 million in series a





About usContact usLegal Information
Copyright 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.